This study provides the first evidence that Fgf9 plays a critical role in the fate determination of BMSCs by facilitating adipogenesis and inhibiting osteogenesis, suggesting that FGF9 is a potential therapeutic target in the treatment of osteoporosis. This evidence concerns the gene FGF9 and osteoporosis.